Related Experiment Video
Updated: Aug 16, 2025

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose
Published on: October 14, 2015
Referral, Genetic Counselling, and BRCA Testing in the Manitoba High-Grade Serous Ovarian Cancer Population,
Kelcey Winchar1, Pascal Lambert2,3, Kirk J McManus2,4
1Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, MB R3A 1R9, Canada.
Insights
Genetic referral and BRCA testing rates for high-grade serous ovarian cancer (HGSOC) patients increased from 2004-2019. However, a minority received genetic counseling or BRCA1/2 testing, impacting treatment decisions.
Area of Science:
- Oncology
- Genetics
- Epidemiology
Background:
- High-grade serous ovarian cancer (HGSOC) is a significant health concern.
- Genetic mutations, particularly BRCA1/2, play a crucial role in HGSOC development and treatment.
- Understanding referral and testing patterns is vital for improving patient care.
Purpose of the Study:
- To determine the rate of genetic referral and BRCA testing in HGSOC patients from 2004-2019.
- To analyze factors influencing genetic referral and testing rates.
- To assess the impact of these rates on clinical decision-making.
Main Methods:
- Population-based cohort study utilizing multiple health registries in Manitoba.
- Inclusion of all women diagnosed with HGSOC between 2004-2019.
- Analysis of data across three distinct time cohorts to identify trends and influencing factors.
Main Results:
- A total of 944 HGSOC patients were included in the study.
- Genetic referral rates fluctuated (20.0% → 56.7% → 36.6%), while overall genetic testing rates increased over the study period.
- Factors such as age, histology, oral contraceptive use, and family history of ovarian cancer positively correlated with referral and testing rates.
Conclusions:
- Genetic referral and BRCA1/2 testing rates for HGSOC patients have increased over time.
- A significant proportion of patients did not receive genetic counseling or BRCA1/2 testing, hindering personalized treatment.
- Further initiatives are required to enhance genetic consultation and testing uptake in HGSOC patients.
Abstract:
(1) Background: The primary objective of this study was to examine the rate of genetic referral, BRCA testing, and BRCA positivity amongst all patients with high-grade serous ovarian cancers (HGSOC) from 2004-2019. The secondary objective was to analyze secondary factors that may affect the rates of referral and testing. (2) Methods: This population-based cohort study included all women diagnosed with HGSOC using the Manitoba Cancer Registry, CervixCheck registry, Medical Claims database at Manitoba Health, the Hospital Discharge abstract, the Population Registry, and Winnipeg Regional Health Authority genetics data. Data were examined for three different time cohorts (2004-2013, 2014-2016; 2017-2019) correlating to practice pattern changes. (3) Results: A total of 944 patients were diagnosed with HGSOC. The rate of genetic referrals changed over the three timeframes (20.0% → 56.7% → 36.6%) and rate of genetic testing increased over the entire timeframe. Factors found to increase rates of referral and testing included age, histology, history of oral contraceptive use, and family history of ovarian cancer. Prior health care utilization indicators did not affect genetic referral or testing. (4) Conclusion: The rate of genetic referral (2004-2016) and BRCA1/2 testing (2004-2019) for patients with a diagnosis of HGSOC increased over time. A minority of patients received a consultation for genetics counselling, and even fewer received testing for a BRCA1/2. Without a genetic result, it is difficult for clinicians to inform treatment decisions. Additional efforts are needed to increase genetics consultation and testing for Manitoban patients with HGSOC. Effects of routine tumour testing on rates of genetic referral will have to be examined in future studies.
More Related Videos
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020